Last quarter, EPS beat estimates by $0.71, yet the stock fell 5.1% that day—$CVS earnings have never been just about whether results beat expectations.
CVS Health will report its 2026 Q3 results before the U.S. market opens on November 4. The earnings call is at 8:00 a.m. Eastern Time (9:00 p.m. Beijing Time on November 4). Consensus EPS is around $1.62–$1.66 (vs. $1.60 in the same quarter last year, up about 1.3% year over year), with revenue around $104.72–$105.04 billion (up about 2.1% year over year). Last quarter’s Q2 is the point of comparison: EPS of $2.58 beat consensus of $1.87 by a wide margin, and revenue of $106.10 billion also topped expectations of $100.03 billion—yet the stock still fell 5.1% on August 5. Full-year guidance currently stands at $7.90–$8.10. The key figure to watch is Aetna’s medical benefit ratio: consensus is 92.4%, versus 92.8% in the same quarter last year; it improved to 87.4% in Q2, and whether that level can hold this time will show how strong the results really are.
I see three possible scenarios: a beat, further improvement in the medical benefit ratio, and an increase in full-year guidance. Only if all three happen can the company turn the narrative around and keep the recovery going. If results merely meet consensus and the ratio does not improve, treat last quarter as a one-off and don’t rush to chase the stock. If EPS comes in near the low end or guidance stays unchanged, reassess the valuation and risk tolerance—don’t try to catch the first move before the market opens. Don’t act on the premarket numbers alone; wait for the earnings call to break down the medical benefit ratio and full-year guidance before making a judgment.
Data as of: 2026-11-01 23:10 UTC
For informational purposes only; not investment advice.
CVS Health will report its 2026 Q3 results before the U.S. market opens on November 4. The earnings call is at 8:00 a.m. Eastern Time (9:00 p.m. Beijing Time on November 4). Consensus EPS is around $1.62–$1.66 (vs. $1.60 in the same quarter last year, up about 1.3% year over year), with revenue around $104.72–$105.04 billion (up about 2.1% year over year). Last quarter’s Q2 is the point of comparison: EPS of $2.58 beat consensus of $1.87 by a wide margin, and revenue of $106.10 billion also topped expectations of $100.03 billion—yet the stock still fell 5.1% on August 5. Full-year guidance currently stands at $7.90–$8.10. The key figure to watch is Aetna’s medical benefit ratio: consensus is 92.4%, versus 92.8% in the same quarter last year; it improved to 87.4% in Q2, and whether that level can hold this time will show how strong the results really are.
I see three possible scenarios: a beat, further improvement in the medical benefit ratio, and an increase in full-year guidance. Only if all three happen can the company turn the narrative around and keep the recovery going. If results merely meet consensus and the ratio does not improve, treat last quarter as a one-off and don’t rush to chase the stock. If EPS comes in near the low end or guidance stays unchanged, reassess the valuation and risk tolerance—don’t try to catch the first move before the market opens. Don’t act on the premarket numbers alone; wait for the earnings call to break down the medical benefit ratio and full-year guidance before making a judgment.
Data as of: 2026-11-01 23:10 UTC
For informational purposes only; not investment advice.
